Please assess the completion status of the following clinical trial:

Trial Title: A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 70 years old~* Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal to (\>=) 10,000 international units per milliliter (IU/mL)~* Must have chronic hepatitis C (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin~* Cannot also be infected with Human Immunodeficiency Virus or hepatitis B~* Must be judged to be in general good health and able to receive Pegasys® and Copegus®~* No drug or alcohol abuse in the last year~* Must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. One of the methods needs to be a 'barrier' method (condom or diaphragm)~* If you are a woman, you cannot be in this study if you are pregnant or nursing~Exclusion Criteria:~* Participation in any clinical trial of a HCV protease inhibitor of any duration~* Prior response to therapy and failure to achieve SVR which was due to treatment non-compliance~* Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis~* Diagnosed or suspected hepatocellular carcinoma~* History of or current evidence of decompensated liver disease~* Participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 24 weeks.
- Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
- Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
- PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week (Type: PLACEBO_COMPARATOR): Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).